1Cuzick J, Cox T. HPV DNA testing in cervical cancer screening : from evidence to policies [ J ]. Gynecol Oncol, 2006,103( 1 ) :8 - 11.
2Silverloo I, Andrae B, Wilander E, et al. Value of high-risk HPV-DNA testing in the triage of ASCUS [ J]. 2009, 88(9) :1006 - 1010.
3Hernandez-Hernandez DM,Omelas Bemal L, Jilnencz M, et al. Association between high risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women [ J ]. Gynecol Oneol,2003,90 ( 2 ) : 310 - 317.
4Syrjanen K, Naud P, Derchain S, et al. Comparing PAP cytology, aided visual inspection, screening colposeopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study [ J ]. Anticancer Res, 2005,25 ( 5 ) :3470 - 3480.
5Sankaranarayanan R, Wesley R, Thara D, et al. Test characteristics of visual inspection with 4% acetic acid ( VIA ) and Lugol, siodine ( VILI ) in cervical cancer screening in Kerala, India [ J ]. Int J Cancer, 2003,106 (3) :404-408.
6Smith JS, Amy M, Rashida K, et al. Age-specific prevalence of infection with human papillomavirus in females : A global review [ J ]. J Adolesc Health,2008,43 (4 Suppl) :S5 - S25.
7Wu SF, Li M, Wang SX, et al. A comparison of four screening methods for cervical neoplasia [ J ]. Int J Gynecol Obstet,2005,91 (2) :189 -193.
8Medeiros LR, Ethur AB, Hilgert JB, et al. Vertical transmission of the human papillomavirus: a systematic quantitative review [ J ]. Cad Saude Publica, 2005,21 (4) :1006 - 1015.
2Silverloo I,Andrae B,W ilander E,et al.Value of high-risk HPV-DNA testing in the triage of ASCUS[J].2009,88(9):1006-1010.
3de Sanjos é S,Diaz M,Castellsagu é X,et al.World-wide prevalence and genotype distribution of cervicalhuman papil-loma virus DNA in women with normal cytology:a meta analysis[J].J Lancet Infect Dis,2007,7(7):453-459.
